ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. dominated the market today, gaining -€0.005 (3.520%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on ProQR Therapeutics N.V..
As a result the target price of 2 € shows a slightly positive potential of 5.71% compared to the current price of 1.89 € for ProQR Therapeutics N.V..
For the coming years our community has positive and negative things to say abot the ProQR Therapeutics N.V. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Company culture" there were negative voices in the community.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | 3.520% | - | - | - | - | - | - |
| Pharming Group | 1.890% | -3.534% | -14.697% | -14.194% | -15.767% | -18.020% | 6.265% |
| Salarius Pharmaceuticals Inc. | -2.830% | -3.738% | -2.830% | -71.389% | -25.766% | -98.474% | -99.994% |
| Ardelyx Inc. | 3.670% | -0.366% | -11.361% | 47.951% | 3.668% | -1.770% | - |
Comments
The comment is under review
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for PRQR provided by MarketBeat